Pharmacy supply in the UK and the questions you will be asked posts 91–106

On post #87 — agreed on the reasoning, with one qualification.

Private prescribing is legal and widespread, including through remote consultation. Pharmacies must satisfy themselves that a prescription is clinically appropriate. Expect to be asked for measurements and history.

Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the kind that comes from remembering a figure instead of looking it up.

Regional variation in NHS: access varies dramatically by region depending on local commissioning decisions and specialist service availability. Postcode determines access risk.

Importing for personal use: importing a prescription-only medicine without a prescription is not lawful. Material sold as research-use-only is not a licensed medicine regardless of content.

Worth separating two things that post #91 runs together.

Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.

post #95 is right about the mechanism and I think understates the practical bit.

Cross-border arrangements: some people source from other EU countries. Rules on import for personal use are changing post-Brexit. Current status requires checking with UKVI.

NHS access has been restricted by commissioning criteria, not by licensing. Specialist weight-management services in many areas require prior weight-loss attempts, BMI thresholds, or other specific criteria.

Compounding pharmacies: UK allows compounding under specific conditions when a licensed product is unavailable. That is not a front-line option but becomes relevant during shortages.

Regional variation in NHS: access varies dramatically by region depending on local commissioning decisions and specialist service availability. Postcode determines access risk.

Importing for personal use: importing a prescription-only medicine without a prescription is not lawful. Material sold as research-use-only is not a licensed medicine regardless of content.

MHRA is the regulator. Licensed incretin analogues are prescription-only medicines. NHS and private prescribing routes exist with materially different access criteria and costs.

Picking up post #99: that is the part I would want checked first.

Occupational health screening: some UK occupations require medical checks. Disclosure of weight-loss medication might be relevant to employment screening; understand your obligations.

On post #99 — agreed on the reasoning, with one qualification.

Private prescribing is legal and widespread, including through remote consultation. Pharmacies must satisfy themselves that a prescription is clinically appropriate. Expect to be asked for measurements and history.

I disagree with the reply above, and I think the disagreement is substantive rather than terminological.

The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.